Beam Therapeutics opened lower at $25.06, compared with its previous close of $25.81. In the last trading session, the stock traded between $23.86 and $25.15. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Beam Therapeutics is now worth
$ 25.74
Resulting in a loss of
$ 74.26 (74.26%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
91.67%
Hold
8.33%
Sell
0%
Markets Today
Today's Change
$-1.78 (-6.88%)
Day High
$25.15
Day Low
$23.86
Day Open
$25.06
Prev Close
$25.81
Volume
12,35,086
1W Return
-13.53%
1M Return
-4.39%
3M Return
-10.50%
6M Return
-24.30%
1Y Return
6.91%
Fundamentals
Market Cap ($ Mn)
2,487
PE Ratio
-
PB Ratio
2.84
PEG Ratio
-
ROE
-7.83%
ROCE
-10.35%
EPS (TTM)
$-1.30
Investment Returns
1 Week
-13.53%
1 Month
-4.39%
3 Months
-10.50%
6 Months
-24.30%
9 Months
-7.53%
Financials
Quarterly
All values in $ Mn
7.5
Mar 25
8.5
Jun 25
9.7
Sep 25
114.1
Dec 25
0.5
Jun 26
0.3
Sep 26
Updates
11Nov
Wedbush raises Beam Therapeutics price target to $33, keeps Outperform
Wedbush maintains an Outperform rating on Beam Therapeutics. Price target increased from $30 to $33. Analyst David Nierengarten issued the update.
Yesterday
4Nov
Beam Therapeutics to present updated sickle cell data at ASH meeting
Beam Therapeutics to present updated BEACON Phase 1/2 data at ASH. Presentation scheduled for December 12-15, 2026 in New Orleans. Risto-cel is an investigational therapy for sickle cell disease. Selected for ASH official press program.
8 days ago
3Nov
Beam Therapeutics Q3 Results: Loss widens 16% YoY, revenue misses
Net loss widened to $1.28 per share, missing analyst estimates by 11.3%. Quarterly revenue collapsed 96.83% YoY to $307 thousand. Revenue missed consensus estimates of $8.752 million by 96.49%. Losses increased 16.36% compared to $1.10 per share in the prior year.
9 days ago
15Oct
HC Wainwright reiterates Buy rating on Beam Therapeutics with $80 target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterated a Buy rating on Beam Therapeutics. The firm maintained its existing price target of $80 per share. The action indicates sustained confidence in the company's investment thesis.
28 days ago
14Oct
Pomerantz investigates Beam Therapeutics over clinical data claims
Pomerantz LLP is investigating Beam Therapeutics for potential securities fraud. Stock price fell $2.83 per share, or 9.54%, on September 8, 2026. Investigation stems from updated Phase 1/2 clinical data for BEAM-302. Press release disclosed Grade 1 ALT and AST elevations despite acceptable safety profile.
1mo ago
23Sep
Pomerantz probes Beam Therapeutics after 9.54% stock drop
Pomerantz LLP investigates Beam Therapeutics for securities fraud. Stock fell 9.54% to $26.83 after adverse clinical data disclosure. Adverse events included Grade 1 ALT and AST elevations in trial. Schall, Brown & Schwartz LLP also investigating similar claims.
